Acrivon Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020
Selling, General & Admin	21.08	8.71	2.47	1.3
Research & Development	46.02	23.95	13.72	1.87
Operating Expenses	67.1	32.66	16.18	3.17
Operating Income	-67.1	-32.66	-16.18	-3.17
Other Expense / Income	-6.72	-1.49	0.06	2.14
Pretax Income	-60.39	-31.17	-16.24	-5.31
Net Income	-60.39	-31.17	-16.24	-5.31
Shares Outstanding (Basic)	22	4	2	1
Shares Outstanding (Diluted)	22	4	2	1
Shares Change	435.63%	136.43%	21.70%	-
EPS (Basic)	-2.74	-7.56	-9.32	-3.70
EPS (Diluted)	-2.74	-7.56	-9.32	-3.70
Free Cash Flow	-43.93	-32.28	-14.22	-2.82
Free Cash Flow Per Share	-1.99	-7.83	-8.16	-1.97
EBITDA	-59.07	-30.07	-15.41	-5.29
Depreciation & Amortization	1.31	1.1	0.83	0.01
EBIT	-60.39	-31.17	-16.24	-5.31

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).